ArticleInflammopharmacology2026
Dioscin-rich extract of Dioscorea floribunda ameliorates metabolic syndrome by improving inflammation-mediated gut, adipose and hepatic dysfunctions: a pre-clinical study.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Metabolic syndrome (MetS), an intricate condition exemplified by obesity, dyslipidemia, insulin resistance, hypertension and liver disease, which is increasingly linked to gut malfunctions and often accompanied by chronic low-grade inflammation. Dioscorea species or yam, are tuberous staple foods in most parts of Africa and Asia. Many species of this plant are traditionally used both as food and as remedies for various chronic disorders. The goal of this study was to perform the pre-clinical evaluation of dioscin-rich extract of Dioscorea floribunda (Dio-FE) against obesity induced-MetS in experimental mice. Aqueous (Dio-FA), hydro-alcoholic (Dio-FHA) and ethanolic (Dio-FE), extracts were prepared from tubers of Dioscorea floribunda. These extracts were subjected to understand their safety and pro-inflammatory cytokines inhibitory potential in cells. Dio-FE, the most potent extract, was further subjected for chemical signature using HPLC method. We further demonstrated the pharmacological role of dioscin, a phytoconstituent in Dio-FE extract against the inflammation in peritoneal macrophages, fat deposition in adipocytes and FFA-induced hepatic steatosis by a significant reduction in intracellular lipid accumulation, TNF-α, and NF-κB protein expression in liver cells. We also examined pharmacological potential of Dio-FE against obesity-induced MetS in C57BL/6 mice model. The in-vitro findings illustrated that Dio-FE was the most potent against inflammation. HPLC of Dio-FE showed the presence of dioscin as a bioactive phytosteroid. The experimental animal study showed that Dio-FE, significantly improved clinically relevant metabolic parameters, production of short-chain fatty acids (SCFAs), preventing leaky gut and also reducing the production of pro-inflammatory cytokines. These findings revealed that Dio-FE, an extract from tuberous staple foods improved obesity, insulin resistance, gut barrier function and liver metabolic parameters associated with MetS through modulation of the low-grade inflammation. These results provide a basis for future clinical investigations of Dio-FE as in addressing MetS.
Indexed as
Identifiers
41996067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.